Treatment of Irgm1−/− mice with the RIPK2 inhibitor GSK583 (Haile et al, 2016; Goncharov et al, 2018) significantly ameliorated the acute colitis symptoms (Figs 7A and B, and EV5A and B). This evidence concerns the gene RIPK2 and colitis.